• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

J&J, Rallybio partner on drug development for rare fetal condition

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 10, 2024 at 06:02: PM
via Biotechnology company Rallybio is partnering with Johnson & Johnson, announcing a collaboration Wednesday to develop new treatments for a rare disorder known as fetal and neonatal alloimmune thrombocytopenia, or FNAIT.

article source
 




Top Bottom
Back
Quote